Log in | Register

E-mail
Company Name

Stiefel Laboratories, Inc. Appoints New President

Loading...
Stiefel Laboratories, Inc. has announced the promotion of William D. (Bill) Humphries to president of the privately-held dermatology company. Stiefel's board of directors elected Humphries to the position at its February 26 meeting. This move marks the first time in the organization's 160-year history that a non-family member has held the position of president.

"This promotion is testament to the board's trust in Bill's proven ability to serve as both an effective and dynamic leader of this company," said Charles W. Stiefel, chairman of the board and CEO, Stiefel Laboratories. "Bill's leadership abilities and extensive pharmaceutical experience will serve the company well as we continue our upward trajectory to achieving our corporate objective of $1 billion in sales next fiscal year. I look forward to working side-by-side with Bill and the rest of our senior executive team as we strive to be the world's most-valued and respected dermatology-focused specialty pharmaceutical company."

As president, Humphries will continue to lead all sales, marketing, strategic communications, public relations and commercial aspects of Stiefel's global business. He also will assume responsibility for Glades Pharmaceuticals, a wholly-owned subsidiary of Stiefel specializing in the sales and marketing of generic pharmaceutical products. This additional responsibility will provide increased flexibility to engage in lifecycle management of Stiefel products.

In his prior position as chief commercial officer, Humphries orchestrated the creation of an integrated global commercial team; helped oversee Stiefel's 2006 acquisition of Connetics Corporation; and played a key role in the 2007 private equity minority investment agreement between Stiefel Laboratories and The Blackstone Group. He was appointed to the company's board of directors in 2006.

Humphries is a 20-year veteran of the pharmaceutical industry, with 18 of those years focused on the specialty of dermatology. He was a vice president at Allergan, Inc., and also worked with Dermik/Rhone-Poulenc-Rorer.Humphries holds a Bachelor of Arts from Bucknell University in Lewisburg, Pa. and an MBA from Pepperdine University in Malibu, Calif. He also holds seats on the boards of BioSouth and the Gwinnett County (Georgia) Chamber of Commerce, and the board of trustees for Georgia Gwinnett College.

Humphries will continue to work out of the company's global sales and marketing headquarters in Duluth, GA.
Join the Discussion
Rate Article:  Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Blogs

The Importance of Fundamentals

The Importance of Fundamentals

Aug 31 | Girish Malhotra, PE, President, EPCOT International

Globally, Johnson & Johnson is known for its integrity and product quality. A few years ago they handled the Tylenol situation extremely well and were commended for it. It is astounding that the year 2010 has become a nightmare for them.  

The Quality Control Unit: Invertebrates Need Not Apply

The Quality Control Unit: Invertebrates Need Not Apply

Aug 30 | The QA Pharm

The Quality Control Unit (QCU) is the only pharmaceutical function that has a job description codified in the CGMP regulations. Don’t you find this remarkable? In fact, an entire section is devoted to describing the responsibility of the QCU and how it is to operate within the organization—namely independently.        

Multimedia

Timothy Cote - Office of Orphan Products Development

Aug 13 | Root

From approving medicines to treating snake bites to Cystic Fibrosis - Dr. Tim Cote describes a special office at the FDA, designed to address needs of people with rare diseases. Timothy Cote, M.D. - Director, Office of Orphan Products Development

Charles River Labs On WuXi PharmaTech Acquisition

Charles River Labs On WuXi PharmaTech Acquisition

May 25 | Video

Charles Rivers Laboratories International Chief Officer talks about the recent WuXi PharmaTech acquisition

Biogen Idec - 2010 Facility of the Year Award Winner - Operational Excellence

Biogen Idec - 2010 Facility of the Year Award Winner - Operational Excellence

Apr 27 | Video

Peter Flinn, Biogen Idec's Senior Director, Global Project Engineering talks to Pharmaceutical Processing's Editor-In-Chief Mike Auerbach about the company's Large-Scale Manufacturing Technology Map Project in Research Triangle Park, North Carolina. The project won the 2010 Operational...

MannKind Corporation - 2010 Facility of the Year Award Winner - Equipment & Process Innovation

MannKind Corporation - 2010 Facility of the Year Award Winner - Equipment & Process Innovation

Apr 28 | Video

Juergen Martens, Ph,D. MannKind Corporation's Corporate Vice President and Chief Technical Officer talks to Pharmaceutical Processing's Editor-In-Chief Mike Auerbach durng INTERPHEX2010 about the company's Technosphere Insulin Manufacturing Facility located in Danbury, Connecticut. The...